Samlyn Capital’s 10x Genomics TXG Stock Holding History

Samlyn Capital’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.3M	Buy	+504,048	New	+$13.2M	0.31%	73

Other funds holding TXG

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Samlyn Capital's TXG Position: Q2 2026 in Review

Samlyn Capital opened a new position in 10x Genomics (TXG) in Q2 2026: 504,048 shares worth $19.3M. The stake represents 0.31% of the portfolio and ranks #73 among its holdings.

368 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Samlyn Capital held 504,048 shares of 10x Genomics worth $19.3M as of Q2 2026.
10x Genomics was a new Samlyn Capital position in Q2 2026.
10x Genomics made up 0.31% of Samlyn Capital's portfolio in Q2 2026, its #73 holding.
368 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Samlyn Capital's 13F filing for Q2 2026, filed 14 Aug 2026.